Orphazyme to give oral explanation as EMA committee decision nears

Biotech company Orphazyme has been called in by the EMA’s expert committee, the CHMP, to answer questions concerning the company’s drug candidate, arimoclomol, on Wednesday at 4 pm. The same drug hope was quashed by the FDA last year.
The European Medicines Agency's headquarters in Amsterdam | Photo: Rob Acket/EMA
The European Medicines Agency's headquarters in Amsterdam | Photo: Rob Acket/EMA
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

At 16:00 CET on Wednesday Feb 23, 2022, Orphazyme will meet with the European Medicines Agency’s (EMA) special committee, the CHMP, to give a so-called ”oral explanation.”

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading